FOLD
Price
$5.69
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
1.83B
32 days until earnings call
LQDA
Price
$13.10
Change
+$0.27 (+2.10%)
Updated
Jun 27 closing price
Capitalization
1.12B
39 days until earnings call
Interact to see
Advertisement

FOLD vs LQDA

Header iconFOLD vs LQDA Comparison
Open Charts FOLD vs LQDABanner chart's image
Amicus Therapeutics
Price$5.69
Change-$0.00 (-0.00%)
Volume$1.47K
Capitalization1.83B
Liquidia
Price$13.10
Change+$0.27 (+2.10%)
Volume$2.09M
Capitalization1.12B
FOLD vs LQDA Comparison Chart in %
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. LQDA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Buy and LQDA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (FOLD: $5.69 vs. LQDA: $13.10)
Brand notoriety: FOLD and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 0% vs. LQDA: 91%
Market capitalization -- FOLD: $1.83B vs. LQDA: $1.12B
FOLD [@Biotechnology] is valued at $1.83B. LQDA’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileLQDA’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • LQDA’s FA Score: 0 green, 5 red.
According to our system of comparison, both FOLD and LQDA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 3 TA indicator(s) are bullish while LQDA’s TA Score has 1 bullish TA indicator(s).

  • FOLD’s TA Score: 3 bullish, 4 bearish.
  • LQDA’s TA Score: 1 bullish, 6 bearish.
According to our system of comparison, FOLD is a better buy in the short-term than LQDA.

Price Growth

FOLD (@Biotechnology) experienced а -0.70% price change this week, while LQDA (@Biotechnology) price change was -0.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

FOLD is expected to report earnings on Jul 31, 2025.

LQDA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($1.83B) has a higher market cap than LQDA($1.12B). LQDA YTD gains are higher at: 11.395 vs. FOLD (-39.597). FOLD has higher annual earnings (EBITDA): 53.6M vs. LQDA (-122.53M). FOLD has more cash in the bank: 251M vs. LQDA (170M). LQDA has less debt than FOLD: LQDA (148M) vs FOLD (443M). FOLD has higher revenues than LQDA: FOLD (543M) vs LQDA (14.1M).
FOLDLQDAFOLD / LQDA
Capitalization1.83B1.12B163%
EBITDA53.6M-122.53M-44%
Gain YTD-39.59711.395-348%
P/E RatioN/AN/A-
Revenue543M14.1M3,851%
Total Cash251M170M148%
Total Debt443M148M299%
FUNDAMENTALS RATINGS
FOLD vs LQDA: Fundamental Ratings
FOLD
LQDA
OUTLOOK RATING
1..100
2064
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
8760
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (64) in the Biotechnology industry is in the same range as LQDA (79) in the Pharmaceuticals Major industry. This means that FOLD’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (68) in the Pharmaceuticals Major industry is in the same range as FOLD (100) in the Biotechnology industry. This means that LQDA’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's SMR Rating (94) in the Biotechnology industry is in the same range as LQDA (99) in the Pharmaceuticals Major industry. This means that FOLD’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as FOLD (87) in the Biotechnology industry. This means that LQDA’s stock grew similarly to FOLD’s over the last 12 months.

LQDA's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as FOLD (100) in the Biotechnology industry. This means that LQDA’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDLQDA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
68%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SDGCX88.600.70
+0.80%
DWS Capital Growth C
POVSX30.530.20
+0.66%
Putnam International Equity A
DESCX22.420.13
+0.58%
DWS ESG Core Equity C
JLGIX22.390.10
+0.45%
JAG Large Cap Growth I
JMVQX35.780.06
+0.17%
JPMorgan Mid Cap Value R4

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with IMVT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
N/A
IMVT - FOLD
43%
Loosely correlated
N/A
RARE - FOLD
42%
Loosely correlated
-2.43%
ROIV - FOLD
42%
Loosely correlated
-1.81%
ATXS - FOLD
41%
Loosely correlated
N/A
CPRX - FOLD
41%
Loosely correlated
-0.50%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with MTVA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then MTVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
+2.10%
MTVA - LQDA
44%
Loosely correlated
-7.35%
KYMR - LQDA
28%
Poorly correlated
-3.48%
ELVN - LQDA
27%
Poorly correlated
-3.95%
FOLD - LQDA
27%
Poorly correlated
N/A
BPMC - LQDA
27%
Poorly correlated
-0.03%
More